Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.62 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.40 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.38 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79188 | 0.99 | S1PR1 (0.60) | S1PR1S1PR3SPHK2SPHK1S1PR4 | |
| SCHEMBL82248 | 0.96 | S1PR1 (0.58) | S1PR1S1PR3SPHK2SPHK1S1PR4 | |
| SCHEMBL80538 | 0.92 | S1PR1 (0.56) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL80887 | 0.90 | S1PR1 (0.54) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL86782 | 0.89 | S1PR1 (0.76) | S1PR1S1PR3SPHK2SPHK1S1PR4 | |
| SCHEMBL2463682 | 0.89 | S1PR1 (0.79) | S1PR1S1PR3SPHK2SPHK1S1PR4 | |
| SCHEMBL2467514 | 0.89 | S1PR1 (0.79) | S1PR1S1PR3SPHK2SPHK1S1PR4 | |
| SCHEMBL2463375 | 0.89 | S1PR1 (0.79) | S1PR1S1PR3SPHK2SPHK1S1PR4 | |
| SCHEMBL81355 | 0.89 | S1PR1 (0.58) | S1PR1S1PR3SPHK2SPHK1S1PR4 | |
| SCHEMBL79184 | 0.89 | S1PR1 (0.58) | S1PR1S1PR3SPHK2SPHK1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | S1PR1 511/4885S1PR3 821/4885SPHK2 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.